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The angiotensin type 2 receptor tonically inhibits angiotensin- The renin-angiotensin system (RAS) is an important
converting enzyme in AT2 null mutant mice. modulator of cardiovascular and renal functions under
Background. Pharmacologic inhibition of the angiotensin- normal conditions, as well as contributing substantially
converting enzyme (ACE) limits angiotensin II (Ang II)-
to pathophysiologic processes within the heart, bloodinduced vasoconstriction and cellular proliferation. There is
vessels, and kidneys [1–4]. Angiotensin-converting en-emerging evidence that some of the beneficial effects of ACE
zyme (ACE) is recognized as having a substantial roleinhibitors may be endogenously available through the angio-
tensin receptor type 2 (AT2). in regulating this system. As such, ACE has become the
Methods. To evaluate whether AT2 modulates ACE activity, central target to modify activity of the RAS through
we used an high-performance liquid chromatography (HPLC)- pharmacologic ACE inhibition, in order to ameliorate
based enzymatic assay in tissues from AT2 knockout mice hypertension, ischemic and hypertrophic cardiac disease,(Agtr2-/y) and cultured cells. These studies were complimented
and progressive renal damage [5–7]. The circulating levelby physiologic studies of pharmacologic inhibition of AT2.
of endogenous ACE in humans is, in part, under theResults. Circulating (C) and tissue ACE activities in heart
control of an intronic insertion/deletion polymorphism in(H), lung (L), and kidney (K) were doubled in Agtr2-/y mice
compared with wild-type mice [162.9 6 17.6 mU/mL (C), 97.7 6 the ACE gene such that the deletion variant is associated
20.7 (H), 6282.1 6 508.3 (L), and 2295.0 6 87.0 (K) mU/g with the highest ACE levels [8]. Endogenous ACE is
tissue for Agtr2-/y vs. 65.3 6 35.4 mU/mL (C), 44.5 6 8.7 (H), also up-regulated by glucocorticoids, fibroblast growth
3392.4 6 495.2 (L), and 1146.1 6 217.3 (K) mU/g tissue for
factor, endothelin, and hypoxia [9–12]. Recently, eleva-wild-type mice, P # 0.05, 0.025, 0.002, and 0.0001, respectively].
tion in ACE activity has been documented in severalAcute pharmacologic inhibition of AT2 [PD123319 (PD), 50
pathophysiologic conditions, including atheroscleroticmg/kg/min, i.v.] significantly increased ACE activity in kidneys
of wild-type mice (1591.2 6 104.4 vs. 1233.6 6 88.0 mU/g tissue vascular disease, failing hearts, and neointimal formation
in saline-infused mice, P , 0.05; P , 0.01 vs. uninfused, wild- after vascular injury [13–15]. Notably, a local increase
type mice). Moreover, ACE activity increased in A10 cells in ACE activity, even in the absence of injury or systemic
exposed to PD (1026 mol/L) together with Ang II (1027 mol/L), alterations, is associated with adverse consequences.
but not with an AT1 antagonist (losartan, 1026 mol/L). This
Thus, transfection of the human ACE gene, which in-heightened ACE activity appears functionally relevant because
creases ACE activity in mouse hearts, leads to cardiacinfusion of angiotensin I caused more prompt hypertension in
hypertrophy (abstract; Aoki et al, Hypertension 30:484a,Agtr2-/y mice than in wild-type littermates. Likewise, infusion
of bradykinin, also a substrate for ACE, caused significantly 1997), whereas transfection into intact rat carotid arteries
less hypotension in Agtr2-/y mice than controls. increases the vessel wall to lumen ratio through cellular
Conclusions. These studies indicate that AT2 functions to hypertrophy [16].
decrease ACE activity tonically, which may, in part, underlie
It is notable that more pronounced parenchymal fi-AT2’s increasingly recognized attenuation of AT1-mediated
brosis is seen in the kidneys of mice with a disruptionactions.
of the gene for the angiotensin type 2 receptor (AT2)
following obstructive injury [17, 18]. These observations
are particularly interesting because the AT2 receptorKey words: ACE inhibition, AT2 receptor, bradykinin, renin-angioten-
sin system, progressive renal disease. has been shown to have vasodilative, antiproliferative,
antihypertrophic, and proapoptotic functions, whichReceived for publication February 26, 1999
have been proposed to exert a brake on the damagingand in revised form September 17, 1999
Accepted for publication October 1, 1999 processes driven by the RAS [19–21]. For example, over-
expression of the AT2 receptor, by transfection into bal-Ó 2000 by the International Society of Nephrology
570
Hunley et al: Angiotensin AT2 receptor inhibits ACE 571
loon-injured rat carotid artery, attenuates neointimal MO, USA), PD 123319 (PD, 1026 mol/L; Research Bio-
chemicals International, Natick, MA, USA), or losartanformation [22]. Conversely, antagonizing the AT2 recep-
tors in hamsters with heart failure significantly heightens (Los; 1026 mol/L; Merck, Piscataway, NJ, USA) for 48
hours. Cells were then harvested and homogenized inthe level of cardiac fibroblast collagen production and
worsens the extent of cardiac interstitial fibrosis [23]. 0.1 mol/L potassium phosphate, pH 8.3, and frozen at
2208C until assay for ACE activity. This dose of Ang IINotably, these disease settings are among the conditions
that have been characterized by elevated ACE activity has previously been shown to induce Ang II-dependent
mRNA levels maximally; likewise, this dose of Los elimi-and also show a characteristic benefit from ACE inhibi-
tion [14, 15, 24, 25]. Therefore, to examine the possibility nated that response [27]. Similarly, the dose of PD123319
was shown to eliminate the response induced by 1027that the AT2 receptor curbs the well-recognized actions
of Ang II by modulating ACE activity, we examined mol/L Ang II in AT2-bearing cells [28].
the circulating and tissue ACE in mice with genetically
Protein determinationdisrupted AT2 receptor.
Protein concentration of each cell suspension was de-
termined spectrophotometrically after solubilization in
METHODS
1% Triton X (Sigma) by the modified Lowry assay (Bio-
Agtr2-/y animals Rad, Melville, NY, USA). Standard solutions of bovine
serum albumin (Sigma) were assayed at each determina-We studied male mice aged 12 to 14 weeks genetically
engineered with a disruption of the AT2 receptor gene, tion to generate a standard curve from which the sample
protein concentration was calculated.located on the X chromosome (Agtr2-/y). These mice
were the offspring of Agtr2 deletion mutants produced
In vivo response of wild-type mice to exogenous AT2in our laboratories by homologous recombination in em-
receptor antagonismbryonic stem cells derived from strain 129/Ola [19]. Chi-
meric males were mated with C57BL/6J females such Wild-type C57BL/6J male mice were anesthetized with
a mixture of ketamine (100 mg/kg body wt, i.p.; Parke-that the genetic background of the mutants consisted
of 129/Ola and C57BL/6J. Wild-type male littermates Davis, Morris Plains, NJ, USA) and xylazine (15 mg/kg
body wt, i.p.; Bayer Corporation, Shawnee Mission, KS,served as the controls. Southern blot analysis of tail DNA
was used to screen for the Agtr2 genotype, as previously USA). The left jugular vein was cannulated with a poly-
ethylene cannula (PE-10 fused to PE-50 tubing; Bectondescribed [19]. Briefly, 10 mg of tail DNA were digested
with BamHI and then hybridized with a [a-32P]dATP- Dickinson, Parsippany, NJ, USA) containing 50 U/mL
heparin in saline, which was passed under the skin andlabeled 1.5 kb BamHI-EcoRI fragment of the Agtr2 ge-
nomic DNA (59-flanking region) as a probe. Using this out through the nape of the neck and fixed in place with
bonding adhesive (Permabond International, Engle-probe, which is outside the 59 end of the targeting vector,
a 9.5 kb band represents the wild-type allele, and a 4.5 kb wood, NJ, USA). The mice were placed in individual
cages for two hours of recovery from anesthesia beforeband represents the mutant allele.
infusions were begun. PE tubing was connected to a
Cell culture swivel to allow free mobility. PD123319 (50 mg/kg body
wt/min in normal saline) or normal saline was infused.A10 rat embryonic aortic smooth muscle cells were
purchased from the American Type Culture Collection This dose of PD123319 has previously been shown to
exert physiologic effects in vivo in rodents [29, 30]. Aftercell repository (Rockville, MD, USA). Our binding stud-
ies in these cells reveal the presence of the AT2 receptor, eight hours, animals were anesthetized with methoxyflu-
rane (Mallinkrodt Veterinary, Inc., Mundelein, IL,as well as the AT1 receptors, and reiterate previous
observations in this cell line, which show expression of USA), and organs were harvested and immediately fro-
zen in liquid nitrogen and stored at 2708C until assay.these receptor subtypes [26]. Cells were cultured at 378C,
under 5% CO2 in Dulbecco’s modified Eagle’s medium
In vivo response of Agtr2-/y animals to exogenous(DMEM) supplemented with 10% heat-inactivated
angiotensin I and bradykinin(558C for 30 min) fetal bovine serum (FBS) and 1%
penicillin G (104 U/mL)/streptomycin (104 mg/mL). Cell Agtr2-/y animals and wild-type male littermates were
anesthetized with Inactin (10 mg/100 g body wt, i.p.;lines were trypsinized [0.25% trypsin-1 mmol/L ethyl-
enediaminetetraacetic acid (EDTA); GIBCO BRL, Life Byk Pharmaceutical, Konstanz, Germany). The carotid
artery and jugular vein were cannulated with polyethyl-Technologies, Grand Island, NY, USA], passaged twice
weekly, and studied at passage 16 to 18. Confluent cell ene cannulae (PE-10 fused to PE-50 tubing; Becton
Dickinson) containing 50 U/mL heparin in saline. Ang Icultures, in 100 mm dishes, were serum deprived for 48
hours before study. Cells were then exposed to angioten- (Sigma) at 0.1 and 1.0 mg/kg body wt and bradykinin
(BK; Sigma) at 100 mg/kg body wt were dissolved insin II (Ang II; 1027 mol/L; Sigma Chemical Co., St. Louis,
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saline immediately before each experiment [31]. The and purity of RNA were assessed by spectrophotometry.
Ten micrograms of total RNA were electrophoresed intotal volume of each injection was adjusted to deliver
15 mL/10 g body wt. Peptides were injected through the 1.2% agarose gels containing 6.6% formaldehyde in 20
mmol/L 3-(N-morpholino)propanesulfonic acid (MOPS),jugular vein, and blood pressure was measured through
the carotid arterial line connected to a pressure trans- 5 mmol/L sodium acetate, and 1 mmol EDTA, pH 7.0.
The RNA was then blotted to a Hybond N1 nylon nucleicducer and blood pressure data collection system (Micro-
Med, Inc., Louisville, KY, USA, and Gould Inc., Valley acid transfer membrane (Amersham, Arlington Heights,
IL, USA) by overnight capillary transfer and was cross-View, OH, USA).
linked to the membrane by ultraviolet irradiation. The
Determination of angiotensin-converting probe used for these studies was a mouse cDNA probe,
enzyme activity ACE.31, which encodes the N-terminal 332 amino acids
of mouse ACE [34]. The probe was labeled withSerum and tissue ACE activities were measured by
high-pressure liquid chromatography (HPLC), as de- [a-32P]dATP by random labeling (Stratagene, La Jolla,
CA, USA). Prehybridization and hybridization were per-scribed by Meng et al [32]. Briefly, tissue samples were
immediately frozen in liquid nitrogen and stored at formed in QuickHyb hybridization buffer (Stratagene)
at 688C. After hybridization, membranes were washed2708C. Tissue was homogenized using a Tempest Virtis-
hear tissue homogenizer (Virtis, Inc., Gardiner, NY, twice for 15 minutes at room temperature in 0.1% so-
dium dodecyl sulfate (SDS)/2 3 standard saline citrateUSA) in 0.02 mol/L potassium phosphate buffer (pH
8.3) and then centrifuged at 40,000 g for 20 minutes, (SSC) and once for 10 minutes at 558C in 0.1% SDA/
0.1 3 SSC. The results were visualized by autoradiogra-followed by two additional cycles of homogenization and
centrifugation, after which the tissue pellet was resus- phy with X-Omat AR film (Eastman Kodak, Rochester,
NY, USA). Loading of RNA was assessed by rehybrid-pended in 0.1 mol/L potassium phosphate buffer (pH
8.3). An aliquot of tissue homogenate was incubated at ization of the same membrane with a cDNA probe for
cyclophillin, a gene that is highly conserved and ubiqui-378C with 500 mL of 0.3 mol/L NaCl, 0.01% Triton X-
100 (Sigma), 1024 mol/L ZnCl2, and 5 mmol/L hippuryl- tously expressed throughout rodent tissues [35]. Relative
amounts of mRNA were quantitated by densitometrichistidine-leucine (HHL; Sigma) in 0.1 mol/L potassium
phosphate buffer (pH 8.3). A second aliquot of tissue scanning of the autoradiograph with an image analysis
system (GelPro; Media Cybernetics, Silver Spring, MD,homogenate was incubated at room temperature for 30
minutes with 1024 mol/L captopril before incubation with USA).
HHL, to determine any non-ACE degradation of HHL
Statistical analysisto hippuric acid (HA). The formation of HA from HHL
by ACE was terminated by the addition of 1 N HCl. Results of each parameter within a group are ex-
pressed as mean 6 sem. For intergroup comparisons,Residual tissue was pelleted by centrifugation at 14,000 g
for one minute, and 500 mL of supernatent was removed, statistical significance was assessed using the unpaired
Student’s t-test. All statistical analyses were performedto which 1.5 mL of ethyl acetate was added. After vigor-
ous vortexing to transfer HA from the aqueous to the using the computer software Statview 4.51 (Abacus Con-
cepts, Inc., Berkeley, CA, USA). Statistical significanceorganic phase, a 1 mL aliquot of ethyl acetate was trans-
ferred to a new tube and dried using a Speed Vac SC100 was taken as P , 0.05.
solvent evaporation apparatus (Savant Instruments, Hol-
brook, NY, USA). Dried samples were then dissolved
RESULTS
into 15% aceteonitrile in 0.1 mol/L ammonium phos-
Circulating and tissue angiotensin-convertingphate buffer (pH 6.8) and applied to an Alltima Phenyl
enzyme activitiesHPLC column (4.6 3 250 mm; Alltech, Deerfield, IL,
USA). Standard solutions of HA (Sigma) in the HPLC Angiotensin-converting enzyme activity was measured
by a recently described, sensitive assay of ACE activitymobile phase were prepared and applied daily to the
HPLC column for calculation of HA generation rates that uses a synthetic ACE substrate and HPLC-based
quantitation of the formed product [32]. In Agtr2-/y mice,by ACE. ACE activity is expressed as nmol/L of HA
formed per minute (mU) per gram of tissue, mU per serum ACE activity was 162.9 6 17.6 versus 65.3 6 35.4
mU/mL in age- and sex-matched wild-type mice (P ,mL of serum, or mU per mg protein of cultured cell
suspensions as previously defined [32, 33]. 0.05). Because ACE exists predominantly as a mem-
brane-bound ectoenzyme expressed largely in the endo-
Northern analysis thelium and certain epithelia, we also investigated
whether this relatively larger pool of membrane-boundTotal RNA was isolated from tissue using a modified
acid guanidium isothiocyanate extraction with RNAzolB ACE is also different in the AT2 mutant mice (Fig. 1)
[36, 37]. ACE activity in tissue homogenates from the(Tel.:Test, Inc., Friendswood, TX, USA). The amount
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Fig. 1. Circulating and tissue angiotensin con-
verting enzyme (ACE) activities in Agtr2-/y
(j) and wild-type mice ( ). Each bar repre-
sents mean 6 se. *P , 0.05; **P , 0.025;
***P , 0.002; ****P , 0.0001.
lung of wild-type mice was 3392.4 6 495.2 mU/g tissue. Effects of AT2 receptor blockade on angiotensin-
converting enzyme in cultured cellsACE activity in Agtr2-/y mice lung was markedly ele-
vated at 6282.1 6 508.3 mU/g of tissue (P , 0.002). A Mutational disruption of the AT2 receptor or pharma-
similarly striking elevation was observed in the kidney cological inhibition of AT2 increases ACE activity in
of Agtr2-/y mice in which ACE activity was more than vivo. To evaluate whether the AT2 receptor indeed re-
doubled at 2295.0 6 87.0 mU/g tissue versus 1146.1 6 sponds at the cellular level by modulating ACE activity,
217.3 mU/g tissue in wild-type mice (P , 0.0001). Cardiac we evaluated cells known to have the AT2 receptor,
ACE is known to be an order of magnitude lower than namely A10 cells [26]. In control A10 cells, ACE activity
was 187.9 6 31.4 mU/mg protein. In A10 cells treatedtissue ACE in the lung and kidney, and other enzymes
with Ang II, ACE activity was markedly reduced tohave been shown to be capable of the cleavage of Ang
85.9 6 24.0 mU/mg protein (P , 0.025 vs. control; Fig. 3).I to Ang II in the heart, especially in the interstitium
In A10 cells treated with Ang II together with the selec-[38]. However, again, a marked elevation in cardiac tissue
tive AT2 receptor antagonist, ACE activity was restoredACE was seen for Agtr2-/y animals (97.7 6 20.7 mU/g
to control values, at 185.9 6 38.1 mU/mg protein (P ,tissue vs. 44.5 6 8.7 in wild-type mice, P , 0.025). Nota-
0.05 vs. Ang II-treated cells, P 5 NS vs. control cells;bly, ACE activity in testes of wild-type and Agtr2-/y mice
Fig. 3), indicating that antagonism of the AT2 receptordid not differ (2319.4 6 200.2 vs. 2202.3 6 169.5 mU/g
prevented the Ang II-induced decrease in ACE activity.tissue, respectively; P 5 NS).
By contrast, cells exposed to Ang II together with the
selective AT1 receptor antagonist, Los, such that onlyEffects of AT2 receptor blockade on angiotensin-
AT2 receptors were available for interaction with Angconverting enzyme in wild-type mice
II, had an ACE activity that was comparable to cells
The AT2 receptor was pharmacologically antagonized treated solely with Ang II, 93.4 6 23.7 mU/mg protein
in normal wild-type mice to address the potential com- (pNS vs. Ang II-treated cells; P , 0.025 vs. control cells;
pensation in the null mutant mice to fetal AT2 disruption P , 0.05 vs. Ang II 1 PD-treated cells). PD alone or
and the relevance of the observed Agtr2-/y phenotype Los alone did not affect ACE activity in these cells.
to adult animals. ACE activity was assayed in wild-type
mice after eight hours of continuous intravenous infusion Blood pressure response to exogenous angiotensin I
of either PD123319, a selective AT2 receptor antagonist, and bradykinin
or normal saline while the mice were conscious. ACE To assess whether the different levels of ACE impart
activity in the kidneys of saline infused mice was 1233.6 6 functional significance, we provided exogenous sub-
88.0 mU/g tissue, which is similar to the value obtained strates for ACE metabolism to wild-type and AT2 null
from unmanipulated, baseline wild-type mice kidneys mutant mice (Fig. 4). Infusion of exogenous Ang I
(1146.1 6 217.3 mU/g of tissue). By contrast, kidney (0.1 mg/kg body wt, i.v.) increased the mean arterial
ACE activity in PD-treated mice increased to 1591.2 6 pressure (MAP) of wild-type controls by a maximum of
104.4 mU/g of tissue (P # 0.05 vs. saline infused wild- 14.0 6 3.1 mm Hg, which occurred at 52.0 6 10.6 seconds
type mice, Fig. 2; P , 0.01 vs. uninfused wild-type mice, after the injection. Although the same dose of Ang I
Fig. 1). A Northern blot of kidney mRNA showed that caused a similar increase in MAP in the AT2 null mutant
the ACE mRNA to cyclophillin ratio of 0.14 6 0.08 in mice (16.0 6 2.3 mm Hg), the peak increase occurred
saline-infused mice tended to increase to an average of much faster at 28.0 6 2.0 seconds (P , 0.05; Fig. 4A).
Infusion of a tenfold higher dose of Ang I (1.0 mg/kg0.22 6 0.06 in PD-infused mice.
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Fig. 2. ACE activity in kidney tissue after an-
tagonism of the AT2 receptor in wild-type
mice. (A) Saline infusion ( ) versus infusion
of PD123319 for eight hours (j). (B) North-
ern blot data of ACE to cyclophilin ratio from
mRNA extracted from saline- and PD-infused
kidneys. *P , 0.05.
Fig. 3. Effects of antagonizing either the Ang II type 1 or 2 receptor
on cellular ACE activity. Cultured A10 cells were incubated with vehicle
( ) or Ang II (1027 mol/L, ) in the presence of either AT2 receptor
antagonists PD123319 (PD, 1026 mol/L, j) or AT1 receptor antagonist,
losartan (Los, 1026 mol/L, ). Each bar represents mean 6 se.
body wt, i.v.) caused a maximum increase in MAP of
26.0 6 3.6 mm Hg at 53.0 6 9.5 seconds in control
mice. Again, although the maximum effect on MAP was
similar in AT2 null mutant mice (20.7 6 2.9 mm Hg),
the effect was more prompt, occurring at 31.0 6 3.6
seconds (P , 0.05).
Bradykinin is another endogenous substrate for ACE,
which normally degrades BK to inactive metabolites. In
these studies, AT2 null mutant mice showed an attenu-
ated vasodilator response after the injection of exoge-
nous BK (Fig. 4B). Wild-type mice decreased their MAP
by 22.0 6 5.3, 29.3 6 5.3, 34.7 6 2.7, 34.0 6 3.5, 30.7 6 1.8,
and 26.7 6 2.4 mm Hg at 0.5, 1, 2, 3, 4, and 5 minutes,
respectively. At the same time points, AT2 null mutant
Fig. 4. Blood pressure response and time course following exogenous
mice decreased their MAP by only 3.3 6 2.4, 13.3 6 8.1, Ang I and bradykinin infusions. (A) Effects of Ang I (0.1 mg/kg body
wt, h, and 1.0 mg/kg body wt, j) in Agtr2-/y as well as in wild-type21.3 6 5.2, 19.3 6 7.7, 22.0 6 6.6, and 17.3 6 2.9 mm Hg
mice (0.1 mg/kg body wt, s, and 1.0 mg/kg body wt, d). (B) Effects of(P , 0.025 for 0.5, 2, and 5 min; P , 0.05 for 3 and bradykinin (100 mg/kg body wt) in Agtr2-/y (j) and wild-type mice
(s). *P , 0.05; **P , 0.025.4 min).
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DISCUSSION mutant mice, and we now show that these mice are char-
acterized by a widespread increase in ACE activityAngiotensin II transduces its effects through the AT1
[17, 18]. Conversely, it is interesting that local over-and AT2 receptor subtypes. Most of the recognized ef-
expression of the AT2 receptor in rat carotid arteriesfects of Ang II such as vasoconstriction, cellular prolifer-
attenuated neointimal formation following balloon in-ation, and matrix deposition occur through the AT1 re-
jury, a perturbation known to induce ACE expressionceptor [1–4]. The role of the AT2 receptor has recently
[15, 22]. Taken together, it appears that a decrease inbeen characterized rather to counter AT1 actions, en-
AT2 unleashes ACE, whereas enhancement of AT2 lim-compassing antipressor, antichronotropic, and proapop-
its cellular proliferation, which, at least in part, may betotic functions [17–23]. Thus, in vivo cardiac overexpres-
due to AT2 limitation of ACE.sion of the AT2 receptor dampens Ang II-induced
To evaluate whether the AT2 effect on ACE persistedpressor effects, whereas in vitro AT2 overexpression
in normal mice, we pharmacologically inhibited AT2dampens vascular smooth muscle cell proliferation [22,
receptors in wild-type animals. AT2 blockade signifi-39]. Mice lacking the AT2 receptor gene manifest more
cantly increased renal tissue ACE activity, which roseparenchymal fibrosis in the kidney following injury, sug-
by some 30% above baseline levels. This increase wasgesting that lack of AT2 facilitates detrimental processes
not seen in saline-infused control mice. ACE mRNA[17, 18]. Such parenchymal damage can be ameliorated
showed a similar tendency. We also studied cells bearingby inhibiting ACE, which lessens vasoconstriction, cellu-
both the AT1 and AT2 receptors. Exposing these cellslar hypertrophy, and proliferation [3–7]. Given that the
to Ang II caused a decrease in ACE activity, which wasemerging function of the AT2 receptor appears to reca-
reversed following concomitant treatment with the AT2pitulate the effects of ACE inhibition and because pre-
receptor antagonist. By contrast, this reversal in ACEliminary studies indicate that ACE activity might be
activity was not seen after antagonizing the AT1 recep-modulated by Ang II receptors (abstract; Berecek et al,
tor. Collectively, these in vivo and in vitro studies suggest
FASEB J 6:1578, 1992), we investigated whether or not
that AT2 tonically decreases ACE activity. Recent stud-
the AT2 receptor specifically impacts ACE.
ies in rats with pressure overload cardiac hypertrophy
We studied mice devoid of the AT2 receptor and found [40] and myocardial infarction [25, 41] complement our
the circulating ACE activity to be uniformly higher in findings. In this setting, increased ACE activity is les-
Agtr2-/y mice, being twice that of wild-type littermates. sened by antagonizing the AT1 receptor, raising the pos-
ACE exists, however, predominantly as a membrane- sibility that AT1 antagonism channels more Ang II to
bound ectoenzyme in the endothelium, and some epithe- AT2, which, in turn, down-regulates ACE [25, 40]. It
lia and releasing mechanisms from this relatively larger remains possible, however, that this ACE decrease re-
pool of membrane-bound ACE into the circulation are flects loss of a direct AT1-mediated increase in ACE,
poorly understood [36, 37]. We therefore examined ACE although there is little support for this notion.
activity in tissue compartments of Agtr2-/y mice. Al- Notably, although ACE activity in testes was also re-
though ACE activity in the lung of Agtr2-/y mice and markably high, no difference was seen between Agtr2-/y
controls was markedly and significantly higher than cir- and wild-type mice. It is possible that AT2 is not suffi-
culating ACE, the remarkable step up in Agtr2-/y mice ciently expressed in testicular tissue and/or that it does
persisted. not contribute to regulation of ACE activity in this organ.
The importance of increased ACE activity is evi- Importantly, ACE exists in two predominant isoforms,
denced by observations that ACE is dynamically regu- somatic and testicular. Somatic ACE (sACE) comprises
lated and is induced in several settings, including pres- the bulk of membrane-bound and circulating ACE and
sure overload ventricular hypertrophy, hypoxia, and consists of two enzymatic domains. Testicular ACE
atherosclerotic coronary artery disease [12–14, 25, 40, (tACE), on the other hand, is limited to the testis and
41]. Even in the absence of other injurious stimuli, Mori- consists of a single enzymatic domain identical to the
shita et al recently showed that doubling vascular ACE carboxy-terminal domain of sACE. In fact, tACE is en-
activity per se in the carotid artery fosters vessel hyper- coded within the last half of the sACE gene, being regu-
trophy [16]. This occurred without an increase in sys- lated by a separate testis-specific promoter in intron 12
temic ACE or blood pressure, reiterating the potential of the sACE gene [45, 46]. The sACE-determined ACE
importance of local ACE as a pathophysiologically rele- activities in human serum, heart, and circulating mono-
vant effector. Genetically driven increase in ACE activ- nuclear cells appear to be regulated by the insertion/
ity, such as that found in patients homozygous for the deletion polymorphism in intron 16 of human sACE,
intronic deletion of the human ACE gene, has also been whereas no correlation is found between that locus and
shown to facilitate more aggressive cardiac and renal tACE-determined ACE activity in human spermatozoa,
damage [42–44]. It is interesting that increased fibrosis/ despite the fact that tACE also encompasses the same
region of the intron [8, 33, 47, 48]. This study comple-damage after renal injury characterizes the AT2 null
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